866-997-4948(US-Canada Toll Free)

Pharmaceutical & Healthcare Annual Deals Analysis 2011

Published By :

GlobalData

Published Date : Mar 2011

Category :

Competitive Analysis

No. of Pages : 107 Pages


GlobalData's “Pharmaceutical & Healthcare Annual Deals Analysis 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on Partnerships, Licensing Agreements, M&As, Equity/Debt Offerings, Private Equity and Venture Financing transactions registered in the pharmaceutical and healthcare industry in 2010. The report presents detailed comparative data on the number of deals and their value in the past five years categorized into deal types, segments, and geographies. Additionally, the report provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry. 

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma eTrack deals database and primary and secondary research. 

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the last five years
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents

1 Table of contents

1.1 List of Tables
1.2 List of Figures

2 Pharmaceutical & Healthcare, Global, Deals Summary
2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2010
2.1.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2010 by Quarter
2.2 Pharmaceutical & Healthcare, Global, by Type, Number of Deals and Deal Values, 2010
2.3 Pharmaceutical & Healthcare, Global, Top Deals, 2010
2.4 Pharmaceutical & Healthcare, Top Deals, Global, Summaries, 2010
2.4.1 Novartis Completes Acquisition Of Additional 52% Stake In Alcon From Nestle
2.4.2 Sanofi-Aventis To Raise Its Bid For The Acquisition Of Genzyme
2.4.3 Novartis Receives Alcon's Board Approval For The Acquisition Of Remaining 23% Stake
2.4.4 Merck Completes The Acquisition Of Millipore
2.4.5 Novartis Completes Public Offering Of Senior Notes For $5000m
2.4.6 HCA Refiles Registration Statement For An Initial Public Offering Of $4,600m
2.4.7 BASF Acquires Cognis From Permira And Goldman Sachs
2.4.8 Astellas Pharma Acquires OSI Pharmaceuticals
2.4.9 Reckitt Benckiser Completes Acquisition Of SSL International
2.4.10 Carlyle Group Completes Acquisition Of NBTY
3 Pharmaceutical & Healthcare, Global, Top Deal Makers, 2010

4 Pharmaceutical & Healthcare, Global, Deal Summary, by Type
4.1 Pharmaceutical & Healthcare, Global, M&A, 2010
4.1.1 Pharmaceutical & Healthcare, Global, M&A, 2010 by Quarter
4.1.2 Top M&A Deals in 2010
4.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2010
4.2 Pharmaceutical & Healthcare, Global, Equity Offering Deals, 2010
4.2.1 Pharmaceutical & Healthcare, Global, Equity Offering Deals, 2010 by Quarter
4.2.2 Pharmaceutical & Healthcare, Global, IPO Deals, 2010
4.2.3 Pharmaceutical & Healthcare, Global, Secondary Offerings Deals, 2010
4.2.4 Pharmaceutical & Healthcare, Global, PIPE Deals, 2010
4.2.5 Pharmaceutical & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2010
4.3 Pharmaceutical & Healthcare, Global, Debt Offering Deals, 2010
4.3.1 Pharmaceutical & Healthcare, Global Debt Offerings, 2010 by Quarter
4.3.2 Pharmaceutical & Healthcare, Global, Public Debt Offerings, 2010
4.3.3 Pharmaceutical & Healthcare, Global, Private Debt Placements, 2010
4.3.4 Pharmaceutical & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2010
4.4 Pharmaceutical & Healthcare, Global, Partnership Deals, 2010
4.4.1 Pharmaceutical & Healthcare, Global, Partnership Deals, 2010 by Quarter
4.4.2 Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, 2010
4.4.3 Pharmaceutical & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$m), 2010
4.4.4 Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$m), 2010
4.4.5 Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$m), 2010
4.4.6 Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$m), 2010
4.5 Pharmaceutical & Healthcare, Global, Licensing Agreements, 2010
4.5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, 2010 by Quarter
4.5.2 Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, 2010
4.5.3 Pharmaceutical & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$m), 2010
4.5.4 Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$m), 2010
4.5.5 Pharmaceutical & Healthcare, Global, Licensing Agreements, by Phase, Number Of Deals and Deal Value (US$m), 2010
4.5.6 Pharmaceutical & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$m), 2010
4.6 Pharmaceutical & Healthcare, Global, Private Equity Deals, 2010
4.6.1 Pharmaceutical & Healthcare, Global, Private Equity Deals, 2010 by Quarter
4.6.2 Top Private Equity Deals in 2010
4.6.3 Pharmaceutical & Healthcare, Global, Private Equity Deals, by Therapy Area, 2010
4.7 Pharmaceutical & Healthcare, Global, Venture Capital Deals, 2010
4.7.1 Pharmaceutical & Healthcare, Global, Venture Financing Deals, 2010 by Quarter
4.7.2 Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2010
4.7.3 Pharmaceutical & Healthcare, Global, Venture Capital, by Therapy Area, 2010
4.7.4 Pharmaceutical & Healthcare, Global, Top VC Backed Companies, Last One Year
4.7.5 Pharmaceutical & Healthcare, Global, Top Venture Financing Firms, 2010
4.7.6 Top Venture Financing Deals in 2010

5 Pharmaceutical & Healthcare, Global, Deal Summary, By Therapy Area
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2010
5.1.1 Pharmaceutical & Healthcare, Global, In Vitro Diagnostics Deals, 2010 by Quarter
5.1.2 Oncology - Deals of the Year
5.2 Pharmaceutical & Healthcare, Global, Central Nervous System Deals, 2010
5.2.1 Pharmaceutical & Healthcare, Global, Central Nervous System Deals, 2010 by Quarter
5.2.2 Central Nervous System - Deals of the Year
5.3 Pharmaceutical & Healthcare, Global, Infectious Disease Deals, 2010
5.3.1 Pharmaceutical & Healthcare, Global, Infectious Disease Deals, 2010 by Quarter
5.3.2 Infectious Disease - Deals of the Year
5.4 Pharmaceutical & Healthcare, Global, Immunology Deals, 2010
5.4.1 Pharmaceutical & Healthcare, Global, Immunology Deals, 2010 by Quarter
5.4.2 Immunology - Deals of the Year
5.5 Pharmaceutical & Healthcare, Global, Cardiovascular Deals, 2010
5.5.1 Pharmaceutical & healthcare, Global, Cardiovascular Deals, 2010 by Quarter
5.5.2 Cardiovascular - Deals of the Year
5.6 Pharmaceutical & Healthcare, Global, Metabolic Disorders Deals, 2010
5.6.1 Pharmaceutical & Healthcare, Global, Metabolic Disorders Deals, 2010 by Quarter
5.6.2 Metabolic Disorders - Deals of the Year
5.7 Pharmaceutical & Healthcare, Global, Dermatology Deals, 2010
5.7.1 Pharmaceutical & Healthcare, Global, Dermatology Deals, 2010 by Quarter
5.7.2 Dermatology - Deals of the Year

6 Pharmaceutical & Healthcare, Deal Summary, By Geography
6.1 Pharmaceutical & Healthcare, North America Region, Deals, 2010
6.1.1 Pharmaceutical & Healthcare, North America Region, Deals, 2010 by Quarter
6.1.2 North America - Deals of the Year
6.2 Pharmaceutical & Healthcare, European Region Deals, 2010
6.2.1 Pharmaceutical & Healthcare, Europe, Deals, 2010 by Quarter
6.2.2 Europe - Deals of the Year
6.3 Pharmaceutical & Healthcare, Asia-Pacific Region, Deals, 2010
6.3.1 Pharmaceutical & Healthcare, Asia-Pacific Region Deals, 2010 by Quarter
6.3.2 Asia-Pacific - Deals of the Year
6.4 Pharmaceutical & Healthcare, Rest of the World (ROW) Deals, 2010
6.4.1 Pharmaceutical & Healthcare, Rest of the World Deals, 2010 by Quarter
6.4.2 Rest of the World - Deals of the Year

7 Pharmaceutical & Healthcare, Global, Top Financial Advisors
7.1 Pharmaceutical & Healthcare, Global, Top Financial Advisors, M&A, 2010
7.2 Pharmaceutical & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2010

8 Further Information
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclosure information
8.5 Disclaimer

List of Table


Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 10
Table 2: Pharmaceutical & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010 12
Table 3: Pharmaceutical & Healthcare, Global, Number Of Deals and Deal Values (%), 2010 13
Table 4: Pharmaceutical & Healthcare, Top Deals, Global, 2010 14
Table 5: Pharmaceutical & Healthcare, Global, Top Deal Makers, Number of Deals and Deal Value (US$m), 2010 17
Table 6: Pharmaceutical & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 18
Table 7: Pharmaceutical & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 19
Table 8: Pharmaceutical & Healthcare, Global, Top M&A Deals, 2010 20
Table 9: Pharmaceutical & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$m), by Therapy Area, 2010 21
Table 10: Pharmaceutical & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 22
Table 11: Pharmaceutical & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 23
Table 12: Pharmaceutical & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 24
Table 13: Pharmaceutical & Healthcare, Global, Top IPOs, 2010 25
Table 14: Pharmaceutical & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 26
Table 15: Pharmaceutical & Healthcare, Global, Top Secondary Offerings, 2010 27
Table 16: Pharmaceutical & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 28
Table 17: Pharmaceutical & Healthcare, Global, Top PIPE Deals, 2010 29
Table 18: Pharmaceutical & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), 2010 30
Table 19: Pharmaceutical & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 31
Table 20: Pharmaceutical & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 32
Table 21: Pharmaceutical & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 33
Table 22: Pharmaceutical & Healthcare, Global, Top Public Debt Offerings, 2010 33
Table 23: Pharmaceutical & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 34
Table 24: Pharmaceutical & Healthcare, Global, Top Private Debt Placements, 2010 35
Table 25: Pharmaceutical & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$m), 2010 36
Table 26: Pharmaceutical & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$m), 2006-2010 37
Table 27: Pharmaceutical & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$m), Q1 2010Q4 2010 38
Table 28: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$m), 2010 40
Table 29: Pharmaceutical & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$m), 2010 41
Table 30: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$m), 2010 42
Table 31: Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, 2010 43
Table 32: Pharmaceutical & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$m), 2010 44
Table 33: Pharmaceutical & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$m), 2010 45
Table 34: Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2010 45
Table 35: Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2010 46
Table 36: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 47
Table 37: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010Q4 2010 48
Table 38: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$m), 2010 49
Table 39: Pharmaceutical & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$m), 2010 50
Table 40: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$m), 2010 51
Table 41: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Phase, 2010 52
Table 42: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$m), 2010 53
Table 43: Pharmaceutical & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$m), 2010 54
Table 44: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2010 54
Table 45: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2010 55
Table 46: Pharmaceutical & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 56
Table 47: Pharmaceutical & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 57
Table 48: Pharmaceutical & Healthcare, Global, Top Private Equity Deals, 2010 58
Table 49: Pharmaceutical & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), 2010 59
Table 50: Pharmaceutical & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 60
Table 51: Pharmaceutical & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 61
Table 52: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2010 62
Table 53: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), 2010 63
Table 54: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, Q1 2010 Q4 2010 64
Table 55: Pharmaceutical & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$m), 2010 65
Table 56: Pharmaceutical & Healthcare, Top Venture Financing Deals, Global, 2010 66
Table 57: Pharmaceutical & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 68
Table 58: Pharmaceutical & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 70
Table 59: Pharmaceutical & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 72
Table 60: Pharmaceutical & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 73
Table 61: Pharmaceutical & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 75
Table 62: Pharmaceutical & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 76
Table 63: Pharmaceutical & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 78
Table 64: Pharmaceutical & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 80
Table 65: Pharmaceutical & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 81
Table 66: Pharmaceutical & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 83
Table 67: Pharmaceutical & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 84
Table 68: Pharmaceutical & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 86
Table 69: Pharmaceutical & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010 88
Table 70: Pharmaceutical & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010 90
Table 71: Pharmaceutical & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 92
Table 72: Pharmaceutical & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$m), Q1 2010Q4 2010 94
Table 73: Pharmaceutical & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 95
Table 74: Pharmaceutical & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010 97
Table 75: Pharmaceutical & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 98
Table 76: Pharmaceutical & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010 100
Table 77: Pharmaceutical & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$m), 2006-2010 101
Table 78: Pharmaceutical & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$m), Q1 2010Q4 2010 103
Table 79: Pharmaceutical & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$m), 2010 104
Table 80: Pharmaceutical & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$m), 2010 105

List of Chart


Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$m), 2006-2010
Figure 2: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010
Figure 3: Pharmaceutical & healthcare, Global, Number Of Deals (%) and Deal Values (%), 2010
Figure 4 Pharmaceutical & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), 2006-2010
Figure 5 Pharmaceutical & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 6: Pharmaceutical & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, 2010
Figure 7: Pharmaceutical & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$m), 2006-2010
Figure 8: Pharmaceutical & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 9: Pharmaceutical & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$m), 2006-2010
Figure 10: Pharmaceutical & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$m), 2006-2010
Figure 11: Pharmaceutical & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$m), 2006-2010
Figure 12: Pharmaceutical & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), 2010
Figure 13: Pharmaceutical & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$m), 2006-2010
Figure 14: Pharmaceutical & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 15: Pharmaceutical & Healthcare, Global, Public Debt Offerings Deals, Number of Deals and Deal Value (US$m), 2006-2010
Figure 16: Pharmaceutical & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$m), 2006-2010
Figure 17: Pharmaceutical & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), 2010
Figure 18: Pharmaceutical & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$m), 2006-2010
Figure 19: Pharmaceutical & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 20: Pharmaceutical & Healthcare, Global, Partnership Deals Break-Up (%), 2010
Figure 21: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$m), 2010
Figure 22: Pharmaceutical & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$m), 2010
Figure 23: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$m), 2010
Figure 24: Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, 2010
Figure 25: Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$m), 2010
Figure 26: Pharmaceutical & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$m), 2006-2010
Figure 27: Pharmaceutical & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 28: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$m), 2010
Figure 29: Pharmaceutical & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$m), 2010
Figure 30: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$m), 2010
Figure 31: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Phase, 2010
Figure 32: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$m), 2010
Figure 33: Pharmaceutical & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$m), 2006-2010
Figure 34: Pharmaceutical & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 35: Pharmaceutical & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, 2010
Figure 36: Pharmaceutical & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$m), 2006-2010
Figure 37: Pharmaceutical & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 38: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Values (%), 2010
Figure 39: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, 2010
Figure 40: Pharmaceutical & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$m), 2010
Figure 41: Pharmaceutical & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$m), 2006-2010
Figure 42: Pharmaceutical & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 43: Pharmaceutical & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$m), 2010, 2006-2010
Figure 44: Pharmaceutical & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 45: Pharmaceutical & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$m), 2006-2010
Figure 46: Pharmaceutical & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010
Figure 47: Pharmaceutical & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$m), 2006-2010
Figure 48: Pharmaceutical & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 49: Pharmaceutical & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$m), 2006-2010
Figure 50: Pharmaceutical & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 51: Pharmaceutical & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$m), 2006-2010
Figure 52: Pharmaceutical & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 53: Pharmaceutical & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$m), 2006-2010
Figure 54: Pharmaceutical & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2010-Q4 2010
Figure 55: Pharmaceutical & Healthcare, North America, Number of Deals and Deal Value (US$m), 2006-2010
Figure 56: Pharmaceutical & Healthcare, North America, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010
Figure 57: Pharmaceutical & Healthcare, Europe, Number of Deals and Deal Value (US$m), 2006-2010
Figure 58: Pharmaceutical & Healthcare, Europe, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010
Figure 59: Pharmaceutical & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$m), 2006-2010
Figure 60: Pharmaceutical & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010
Figure 61: Pharmaceutical & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$m), 2006-2010
Figure 62: Pharmaceutical & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$m), Q1 2010-Q4 2010
Figure 63: Pharmaceutical & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$m), 2010
Figure 64: Pharmaceutical & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$m), 2010

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *